India Electric Rickshaw Charger Market Analysis by Trends, Size, Share, Growth Opportunities, and Emerging Technologies It is given that with the rising demand for mobile phones, the demand for the chargers of the handsets will also increase. It is because of the fact that the first is dependent on the second for its continuous and efficient working. It was just an example to get you going, but the blog is not about mobile or mobile chargers, this is about chargers of electric rickshaws in India. Let us start with the blog. The same philosophy of mobile and their chargers will apply to the chargers of electric rickshaws. And, if we talk about the demand for these chargers in India, it is extremely high or we can say the highest. India Overtakes China in terms of E- Rickshaws India has the greatest number of e-rickshaws hurling on the roads and it is overtaken China in the e-rickshaw revolution. In the context of urban transportation, battery-operated e-rickshaws, have definably proved to be a game-changer, altering last-mile connectivity. These vehicles offer a popular transportation mode, serving as a workable alternative to conventional auto-rickshaws while making substantial contributions for the reduction of air and noise pollution. There is an ever-increasing popularity of battery e-rickshaws in India. The total value of the electric e-rickshaw will reach USD 456.2 million by the end of this decade. This proves that there is a tremendous potential for electric rickshaws and subsequently for electric rickshaw chargers as well The demand for EVs in India has increased greatly in in the recent years And, 95% of the total electric vehicles sold in India were battery powered electric rickshaws. Get More Insights: https://www.psmarketresearch.com/market-analysis/india-electric-rickshaw-charger-market Good for Loading Goods as Well These are not just used for passenger transportation, e-rickshaws are also coming good for transporting goods in India. E-rickshaw loaders, with cargo compartments, are perfect for intra-city and last-mile deliveries. These provide environmentally friendly substitute to diesel-powered vans and mini-trucks. The extensive acceptance of battery e-rickshaws will revolutionize mobility in the country. With striving initiatives of the union government and investments in infra, the demand for electric rickshaws will keep on growing in the years to come. Coming to a Conclusion With the rising demand for electric rickshaws in India, the demand for chargers will also rise, as the two are dependent on each other, as the mobile and its charger, the one we talked abut at the beginning of the blog.

Europe Lithium Ion Battery Market Share, Segmentation and Forecast to 2030 The Europe Lithium Ion Battery Market lithium ion battery market was valued at USD 5,504.76 million in 2022 and is expected to reach the value of USD 17,139.84 million by 2030, at a CAGR of 15.30% during the forecast period. Europe Lithium Ion Battery Market Analysis and Size Lithium ion battery is an evolving technology of interest. Small lithium ion battery is extensively used in portable electronic devices, and some lithium ion battery has been manufactured to power EVs. Lithium ion battery is a popular choice of rechargeable battery for use in several applications such as automobiles and stationary applications for offering uninterruptable power supply. State of Health (SoH) and State of Charge (SoC) are significant metrics of a lithium ion battery that can help in both battery diagnostics and prognostics for ensuring prolonged lifetime and high reliability. Get sample of the report https://www.databridgemarketresearch.com/request-a-sample/?dbmr=europe-lithium-ion-battery-market Data Bridge Market Research analyses that the lithium ion battery market was valued at USD 5,504.76 million in 2022 and is expected to reach the value of USD 17,139.84 million by 2030, at a CAGR of 15.30% during the forecast period. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include in-depth expert analysis, geographically represented company-wise production and capacity, network layouts of distributors and partners, detailed and updated price trend analysis and deficit analysis of supply chain and demand. Europe Industrial Lithium Ion Battery Market Scope The lithium ion battery market is segmented on the basis of type, product type, component, power capacity, product, voltage and vertical. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications. Type • Lithium Cobalt Oxide (LCO) • Lithium Manganese Oxide (LMO) • Lithium Nickel Manganese Cobalt Oxide (LI-NMC) • Lithium Iron Phosphate (LFP) • Lithium Nickel Cobalt Aluminum Oxide (NCA) • Lithium Titanate Oxide (LTO) Product Type • Component of Lithium Battery • Cells • Battery Packs • Portability • Stationary • Portable • Component • Anode • Natural Graphite • Artificial Graphite • Another Anode Material • Cathode • Separator • Electrolytic • Separator • Current Collector • Other Material Power Capacity • Below 3000 mAh • 3000 mAh to 10000 mAh • 10000 mAh to 60000 mAh • Above 60000 mAh Voltage • Low (Below 12V) • Medium (12V-36V) • High (Above 36V) Vertical • Automotive • Plug-in Hybrid Vehicles • Consumer Electronics • Smartphones • UPS • Laptops • Others • Aerospace and Defense • Commercial Aircraft • Industrial • Mining Equipment • Construction Equipment • Automated Guided Vehicles and Automated Mobile Robots • Construction • Power • Telecom • Marine • Commercial • Tourism • Others Lithium Ion Battery Market Regional Analysis/Insights The lithium ion battery market is analyzed and market size insights and trends are provided by country, type, product type, component, power capacity, product, voltage and vertical as referenced above. The countries covered in the lithium ion battery market report are Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe. Germany is anticipated to dominate the Europe lithium ion battery market due to the presence of large number of electric vehicles in this region. Moreover, growing usage of lithium-ion batteries in electric vehicles, energy storage systems and consumer electronics will likely to increase the growth rate of the market in this region. Competitive Landscape and Lithium Ion Battery Market Share Analysis The lithium ion battery market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to lithium ion battery market. Some of the major players operating in the lithium ion battery market are: • Saft (France) • Lithium Energy Japan (Japan) • Tianjin Lishen Battery Co., Ltd. (China) • Shenzhen A&S Power Technology Co., Ltd. (China) • LITHIUMWERKS (Europe) • GlobTek, Inc. (U.S.) • BYD Company Ltd (China) • Panasonic Corporation (Japan) • LG Chem (South Korea) • VARTA Microbattery GmbH (Germany) • Dalian CBAK Power Battery Co., Ltd (China) • TOSHIBA CORPORATION (Japan) • CALB USA Inc. (U.S.) • Shenzhen BAK Technology Co., Ltd. (China) • Contemporary Amperex Technology Co., Limited (China) • A123 Systems LLC (U.S.) • Amperex Technology Limited (China) • XALT Energy (Switzerland) • Leclanche (Switzerland) Get Full Access to the Report https://www.databridgemarketresearch.com/reports/europe-lithium-ion-battery-market MAJOR TOC OF THE REPORT Chapter One: Introduction Chapter Two: Market Segmentation Chapter Three: Market Overview Chapter Four: Executive Summary Chapter Five: Premium Insights Chapter Six: Europe Lithium Ion Battery Market Get TOC Details https://www.databridgemarketresearch.com/toc/?dbmr=europe-lithium-ion-battery-market About Us: https://www.databridgemarketresearch.com/reports/global-soybean-derivatives-market https://www.databridgemarketresearch.com/reports/global-retractable-awnings-market https://www.databridgemarketresearch.com/reports/global-pharmaceutical-packaging-equipment-market https://www.databridgemarketresearch.com/reports/global-biodegradable-mulch-film-market Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market Contact: Data Bridge Market Research Tel: +1-888-387-2818 Email: Sopan.gedam@databridgemarketresearch.com

Li-Ion Battery Market Analysis by Trends, Size, Share, Growth Opportunities, and Emerging Technologies The size of the lithium-ion battery market was valued at USD 49.6 billion in 2022, and it will grow at a CAGR of 16.3% in the years to come, to reach USD 165.6 billion by 2030, as per P&S Intelligence. The U.S. had a higher revenue share, about 90%, in the recent past, in North America. The high prerequisite for these kind of batteries in the nation is credited to the extensive use of consumer electronics and electric vehicles. The increasing sales of EVs in the nation are largely driven by supportive government policies and strict targets for plummeting GHG emissions. Furthermore, the nation’s consumer electronics industry is matured and captures a noticeable share of revenue. Moreover, cutting-edge technologies, including IoT and home automation, will similarly thrive the requirement for Li-ion batteries in the U.S. Browse detailed - https://www.psmarketresearch.com/market-analysis/lithium-ion-battery-market Increasing changing lifestyle preference, middle-class population, inclination toward the use of smart electronic devices are the key factors supporting the high requirement for lithium-ion batteries for electronic consumer products. Moreover, governments globally are increasingly supporting digitalization, promoting the use of numerous electronic devices. Moreover, telecom companies are working on 5G for improved connectivity. It is because of the increasing requirement for renewable energy, the demand of the lithium-ion batteries will grow significantly all over the world.

Bacteriophage therapy market Growth Analysis and Forecast by 2035 With the ever-increasing burden of antimicrobial resistance, the focus of the research community has shifted towards the development of alternatives for the treatment of infectious diseases. One of such alternatives is bacteriophage therapeutics. The innovators suggests that the success of these therapies lies in the effectiveness of phages to target the desired bacterial strains. The financial opportunity within the bacteriophage therapeutics market has been analyzed across the following segments:  Type of Therapeutic Area  Infectious Diseases  Oncological Disorders  Other Disorders  Distribution by Route of Administration  Oral Route  Rectal Route  Intravesical Route  Topical Route  Key Geographical Regions  North America  Europe  Asia-Pacific  Latin America  Middle East and North Africa The “Bacteriophage Therapies Market, 2022-2035” report features the following companies, which we identified to be key players in this domain:  Adaptive Phage Therapeutics  ContaFect  Eliava BioPreparations  Micreos  NPO Microgen  Phagelux  Pherecydes Pharma Table of Content 1. PREFACE 2. EXECUTIVE SUMMARY 3. INTRODUCTION 4. BACTERIO-PHAGE THERAPY: MARKET LANDSCAPE 5. BACTERIO-PHAGE THERAPEUTICS: DEVELOPER LANDSCAPE 6. COMPANY AND DRUG PROFILES 7. CLINICAL TRIAL ANALYSIS 8. PATENT ANALYSIS 9. PUBLICATION BENCHMARKING ANALYSIS 10. ACADEMIC GRANTS ANALYSIS 11. FUNDING AND INVESTMENT ANALYSIS 12. PARTNERSHIPS AND COLLABORATIONS 13. START-UP HEALTH INDEXING 14. MARKET FORECAST AND OPPORTUNITY ANALYSIS 15. CONCLUSION 16. EXECUTIVE INSIGHTS 17. APPENDIX I: TABULATED DATA 18. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS For additional details, please visit https://www.rootsanalysis.com/reports/bacteriophage-therapy-market.html Learn from experts: do you know about these emerging industry trends? Rare Kidney Disorders: Future Miracle Drugs Smart pharmaceutical and healthcare labels: Lets trace medicines from its origin Learn from our recently published whitepaper: - Next Generation Biomanufacturing – The Upcoming Era of Digital Transformation About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Learn more about Roots Analysis consulting services: Roots Analysis Consulting - the preferred research partner for global firms Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com #bacteriophagetherapeutics #bacteriophagetherapies #bacteriophagemarket #Marketresearch #MarketInsights

Latest news on Exosome Therapeutics market Research Report by 2035 Driven by the development of novel platforms and advanced technologies along with consistent efforts of the stakeholders in research and development of exosome therapeutics which is set to see some FDA approved therapies in this decade A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below):  Type of Therapeutic  Allogeneic Therapy  AutologousTherapy  Target Indication(s)  Degenerative Meniscal Injury  Dystrophic Epidermolysis Bullosa  Fistula Perianal  Retinitis Pigmentosa  Therapeutic Area  Dermatological Disorders  Muscoskeletal Disorders  Ophthalmic Diseases  Rectal Disorders  Route of Administration  Fistula Tract  Intra-articular  Intra-ocular  Geography  North America  Europe  Asia-Pacific and Rest of the World The Exosome Therapeutics Market, 2022-2040 report features the following companies, which we identified to be key players in this domain:  Codiak BioSciences  Coya Therapeutics  Curexsys  EV Therapeutics  Evox Therapeutics  SHIFTBIO  AEGLE Therapeutics  AVEM Healthcare  Cellular Biomedicine Group  OBCTCD24  ReNeuron  Stem Cell Medicine Table of Contents 1. Preface 2. Executive Summary 3. Introduction 4. Market Landscape 5. Company Profiles 6. Drug Profiles 7. Clinical Trial Analysis 8. Academic Grants Analysis 9. Global Event Analysis 10. Partnerships and Collaborations 11. Funding and Investments 12. Start-up Health Indexing 13. Case Study: Exosome Development and Manufacturing Service Providers 14. Drug Failure Analysis 15. Market Forecast 16. Executive Insights 17. Appendix 1: Tabulated Data 18. Appendix 2: List of Companies and Organizations Key Questions Answered  Who are the leading industry and non-industry players engaged in the development of exosome therapy?  Which are the key drugs being developed across early and late stages of development?  What are the key agendas being discussed in various global events / conferences related to exosomes?  What kind of partnership models are commonly adopted by industry stakeholders?  Which are the leading funding institutes / centers supporting the research related to exosome therapies?  Which geographies are the most active in conducting clinical trials related to exosome therapeutics?  How is the current and future market opportunity, related to exosome therapies likely to be distributed across key market segments? To view more details on this report, click on the link https://www.rootsanalysis.com/reports/exosome-therapeutics-market.html News article Smart Pharmaceutical and Healthcare Labels Market Learn from experts: do you know about these emerging industry trends? Unlocking the Potential of Digital Twins in Healthcare: Benefits, Challenges and Opportunities Digital Therapies: The “Digital Pills” of current generation About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Learn more about Roots Analysis consulting services: Roots Analysis Consulting - the preferred research partner for global firms Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com #exosometherapy #exosomediagnostics #exosomecompanies #MarketResearch #MarketInsights

Bacteriophage therapy market Professional Survey Report by 2035 With the ever-increasing burden of antimicrobial resistance, the focus of the research community has shifted towards the development of alternatives for the treatment of infectious diseases. One of such alternatives is bacteriophage therapeutics. The innovators suggests that the success of these therapies lies in the effectiveness of phages to target the desired bacterial strains. The financial opportunity within the bacteriophage therapeutics market has been analyzed across the following segments:  Type of Therapeutic Area  Infectious Diseases  Oncological Disorders  Other Disorders  Distribution by Route of Administration  Oral Route  Rectal Route  Intravesical Route  Topical Route  Key Geographical Regions  North America  Europe  Asia-Pacific  Latin America  Middle East and North Africa The “Bacteriophage Therapy Market, 2022-2035” report features the following companies, which we identified to be key players in this domain:  Adaptive Phage Therapeutics  ContaFect  Eliava BioPreparations  Micreos  NPO Microgen  Phagelux  Pherecydes Pharma Table of Content 1. PREFACE 2. EXECUTIVE SUMMARY 3. INTRODUCTION 4. BACTERIO-PHAGE THERAPY: MARKET LANDSCAPE 5. BACTERIOPHAGE THERAPEUTICS: DEVELOPER LANDSCAPE 6. COMPANY AND DRUG PROFILES 7. CLINICAL TRIAL ANALYSIS 8. PATENT ANALYSIS 9. PUBLICATION BENCHMARKING ANALYSIS 10. ACADEMIC GRANTS ANALYSIS 11. FUNDING AND INVESTMENT ANALYSIS 12. PARTNERSHIPS AND COLLABORATIONS 13. START-UP HEALTH INDEXING 14. MARKET FORECAST AND OPPORTUNITY ANALYSIS 15. CONCLUSION 16. EXECUTIVE INSIGHTS 17. APPENDIX I: TABULATED DATA 18. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS For additional details, please visit https://www.rootsanalysis.com/reports/bacteriophage-therapy-market.html You may also be interested in the following titles: Cannabis Testing Market Key Trends in Non-Viral Transfection Market CAR-T Cell Therapy Market Roots Analysis Consulting - the preferred research partner for global firms About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com #bacteriophagetherapy #bacteriophagetherapeutics #phagetherapy #MarketResearch #MarketInsights

Medical Device Coatings market 2022 – Industry Growth by 2035 Roots Analysis has done a detailed study on “Medical Device Coatings and Surface Modification Technologies Market, 2023-2035”, covering key aspects of the industry’s evolution and identifying potential future growth opportunities Key Market Insights  Currently, more than 85 companies provide coatings that serve a wide array of functions and are compatible with a diverse array of substrate materials; majority of such players have entered this domain post 2,000  Companies engaged in this industry provide a wide range of coating materials for different types of medical devices; of these, close to 70% of the coatings are being offered for medical implants  In order to gain an edge in this competitive industry, coating providers are continuously undertaking initiatives to upgrade their existing material offerings and coating solutions for medical devices  Presently, more than 115 surface modification technologies and coating solutions are being offered by players to enhance the surface functions and resistance of medical devices  The current market landscape is highly fragmented, featuring the presence of both new entrants and established players across key geographical regions; majority of the players are based in the US  In pursuit of gaining a competitive edge, developers are making an active effort to incorporate advanced technologies into their respective portfolios of coatings / technologies and comply with evolving industry needs  The rising interest of stakeholders in surface modification of medical devices and coating solutions is reflected by the increasing number of partnerships established between various industry and non-industry players  Built on our intellectual capital, we have proposed a proprietary framework that can be applied to strengthen the strategic planning processes and risk management within the industry  With the rising demand for medical device coating solutions and services, the affiliated market for service providers is expected to grow at a steady annualized rate of 7.7% over the coming decade  The opportunity associated with the medical device coatings market is expected to be well distributed among players of different company sizes, with majority of the revenue being coming in from developed regions. Table of Contents 1. PREFACE 1.1. Scope of the Report 1.2. Market Segmentation 1.3. Research Methodology 1.4. Key Questions Answered 1.5. Chapter Outlines 2. EXECUTIVE SUMMARY 3. INTRODUCTION 3.1. Chapter Overview 3.2. Medical Device Coatings 3.2.1. Types of Medical Device Coatings 3.2.2. Lubricious Coatings 3.2.3. Antimicrobial Coatings 3.2.4. Hydrophilic Coatings 3.2.5. Advantages and Disadvantages of Medical Device Coatings 3.3. Surface Modification Technologies 3.3.1. Types of Surface Modification Technologies 3.3.2. Advantages and Disadvantages of Surface Modification Technologies 3.4. Future Perspectives 4. MEDICAL DEVICE COATING PROVIDERS: MARKET LANDSCAPE 4.1. Chapter Overview 4.2. Medical Device Coatings Providers: Overall Market Landscape 4.2.1. Analysis by Year of Establishment 4.2.2. Analysis by Company Size 4.2.3. Analysis by Location of Headquarters 4.2.4. Analysis by Type of Company 4.2.5. Analysis by Type of Medical Device(s) Coated 4.2.6. Analysis by Nature of Coating Material(s) 4.2.7. Analysis by Type of Coating Material(s) 4.2.8. Analysis by Type of Coating(s) 4.2.9. Analysis by Type of Coating Function(s) 4.2.10. Analysis by Type of Compatible Substrate(s) 4.2.11. Analysis by Service(s) Offered 4.2.12. Analysis by Additional Feature(s) Offered 5. COMPANY COMPETITIVENESS ANALYSIS 5.1. Chapter Overview 5.2. Assumptions and Key Parameters 5.3. Methodology 5.4. Medical Device Coatings Providers: Company Competitiveness Analysis 5.4.1. Competitiveness Analysis: Very Small Companies 5.4.2. Competitiveness Analysis: Small Companies 5.4.3. Competitiveness Analysis: Mid-sized Companies 5.4.4. Competitiveness Analysis: Large Companies 5.4.5. Competitiveness Analysis: Very Large Companies 6. SURFACE MODIFICATION TECHNOLOGIES AND COATING SOLUTIONS: MARKET LANDSCAPE 6.1. Chapter Overview 6.2. Surface Modification Technologies and Coating Solutions: Overall Market Landscape 6.2.1. Analysis by Type of Medium(s) for Modification 6.2.2. Analysis by Type of Trademark Right 6.2.3. Analysis by Type of Surface Modification Process(s) Employed 6.2.4. Analysis by Type of Device(s) Coated 6.2.5. Analysis by Type of Medical Device(s) Coated 6.2.6. Analysis by Nature of Coating Material(s) 6.2.7. Analysis by Type of Coating(s) Applied 6.2.8. Analysis by Type of Resistance(s) Offered 6.2.9. Analysis by Type of Compatible Substrate(s) 6.2.10. Analysis by Additional Feature(s) Offered 6.3. Medical Device Surface Modification Technologies and Coating Solutions: Developer Landscape 6.3.1. Analysis by Year of Establishment 6.3.2. Analysis by Company Size 6.3.3. Analysis by Location of Headquarters 6.3.4. Most Active Players: Analysis by Number of Products Offered 7. PRODUCT COMPETITIVENESS ANALYSIS 7.1. Chapter Overview 7.2. Assumptions and Key Parameters 7.3. Methodology 7.4. Product Competitiveness Analysis 7.4.1. Product Competitiveness Analysis: Technologies 7.4.1.1. Technologies Developed by Very Small and Small Companies 7.4.1.2. Technologies Developed by Mid-sized Companies 7.4.1.3. Technologies Developed by Large and Very Large Companies 7.4.2. Product Competitiveness Analysis: Coating Solutions 7.4.2.1. Coating Solutions Developed by Very Small and Small Companies 7.4.2.2. Coating Solutions Developed by Mid-sized Companies 7.4.2.3. Coating Solutions Developed by Large and Very Large Companies 8. MEDICAL DEVICE COATING PROVIDERS: COMPANY PROFILES 8.1. Chapter Overview 8.2. Advanced Coating 8.2.1. Company Overview 8.2.2. Recent Developments and Future Outlook 8.3. Biocoat 8.3.1. Company Overview 8.3.2. Recent Developments and Future Outlook 8.4. Evonik Health Care 8.4.1. Company Overview 8.4.2. Recent Developments and Future Outlook 8.5. Formacoat 8.5.1. Company Overview 8.5.2. Recent Developments and Future Outlook 8.6. Harland Medical Systems 8.6.1. Company Overview 8.6.2. Recent Developments and Future Outlook 8.7. Para-Coat Technologies 8.7.1. Company Overview 8.7.2. Recent Developments and Future Outlook 8.8. Specialty Coating Systems 8.8.1. Company Overview 8.8.2. Recent Developments and Future Outlook 8.9. SurModics 8.9.1. Company Overview 8.9.2. Recent Developments and Future Outlook 8.10. TUA Systems 8.10.1. Company Overview 8.10.2. Recent Developments and Future Outlook 9. PARTNERSHIPS AND COLLABORATIONS 9.1. Chapter Overview 9.2. Partnership Models 9.3. List of Partnerships and Collaborations 9.3.1. Analysis by Year of Partnership 9.3.2. Analysis by Type of Partnership 9.3.3. Analysis by Type of Partner 9.3.4. Analysis by Geography 9.3.5. Most Active Players: Analysis by Number of Partnerships 10. MEDICAL DEVICE COATING PROVIDERS: PESTLE ANALYSIS 10.1. Chapter Overview 10.2. Methodology 10.3. Key Factors 10.3.1. Political Factors 10.3.2. Economical Factors 10.3.3. Sociological Factors 10.3.4. Technological Factors 10.3.5. Legal Factors 10.3.6. Environmental Factors 10.4. PESTLE Analysis: Medical Device Coating Providers 10.4.1. Biocoat 10.4.2. Biomerics 10.4.3. Diamond-MT 10.4.4. Evonik Health Care 10.4.5. Fisher Barton 10.4.6. Formacoat 10.4.7. Freudenberg 10.4.8. Harland Medical Systems 10.4.9. Master Bond 10.4.10. Materion 10.4.11. N8 Medical 10.4.12. Para-Coat Technologies 10.4.13. Specialty Coating Systems 10.4.14. SurModics 10.4.15. Tractivus 10.5. Concluding Remarks 11. MARKET FORECAST 11.1. Chapter Overview 11.2. Key Assumptions and Forecast Methodology 11.3. Global Medical Device Coatings Market, 2023-2035 11.3.1. Global Medical Device Coatings Market: Distribution by Type of Medical Devices Coated, 2023 and 2035 11.3.1.1. Medical Device Coatings Market for Class I Devices, 2023-2035 11.3.1.2. Medical Device Coatings Market for Class II Devices, 2023-2035 11.3.1.3. Medical Device Coatings Market for Class III Devices, 2023-2035 11.3.2. Global Medical Device Coatings Market: Distribution by Type of Coating Material, 2023 and 2035 11.3.2.1. Medical Device Coatings Market for Polymer Coatings, 2023-2035 11.3.2.2. Medical Device Coatings Market for Metal Coatings, 2023-2035 11.3.2.3. Medical Device Coatings Market for Other Coatings, 2023-2035 11.3.3. Global Medical Device Coatings Market: Distribution by Company Size, 2023 and 2035 11.3.3.1. Medical Device Coatings Market for Very Small Companies, 2023-2035 11.3.3.2. Medical Device Coatings Market for Small Companies, 2023-2035 11.3.3.3. Medical Device Coatings Market for Mid-sized Companies, 2023-2035 11.3.3.4. Medical Device Coatings Market for Large Companies, 2023-2035 11.3.3.5. Medical Device Coatings Market for Very Large Companies, 2023-2035 11.3.4. Global Medical Device Coatings Market: Distribution by Key Geographical Regions, 2023 and 2035 11.3.4.1. Medical Device Coatings Market in North America, 2023-2035 11.3.4.2. Medical Device Coatings Market in Europe, 2023-2035 11.3.4.3. Medical Device Coatings Market in Asia, 2023-2035 11.3.4.4. Medical Device Coatings Market in the Rest of the World, 2023-2035 12. CONCLUDING REMARKS 13. EXECUTIVE INSIGHTS 13.1. Chapter Overview 13.2. Biocoat 13.2.1. Company Snapshot 13.2.2. Interview Transcript: Mark Eberhardt, Senior Director of Marketing 13.3. N8 Medical 13.3.1. Company Snapshot 13.3.2. Interview Transcript: Carl Genberg, Chief Scientific Officer 13.4. VaporTech 13.4.1. Company Snapshot 13.4.2. Interview Transcript: David Wayne, Director of Sales and Marketing 14. APPENDIX 1: TABULATED DATA 15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS To view more details on this report, click on the link: https://www.rootsanalysis.com/reports/medical-device-coatings-market.html You may also be interested in the following titles: Cell Therapy Manufacturing Market Global TCR Therapy Market About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com #MedicalDeviceCoatingsmarket #MedicalDeviceCoatingsmarketGrowth #MedicalDeviceCoatings #antimicrobialcoatingsformedicaldevices #surfacetreatmenttechnologies

Exosome Therapeutics market Growth Analysis and Forecast by 2035 Roots Analysis has done a detailed study on Exosome Therapeutics Market, 2022-2040, covering key aspects of the industry and identifying future growth opportunities Key Market Insights  Close to 60 players, worldwide, have taken initiatives to develop exosome therapeutics; the market is characterized by the presence of start-ups and small companies  The current pipeline features more than 120 exosome therapeutics that are being evaluated across different phases of development; most of these are designed for intravenous administration  3,000+ patients have been recruited / enrolled in clinical trials evaluating exosome related therapies and biomarkers across different geographies  More than 530 grants have been awarded for the ongoing R&D efforts for exosome therapeutics; University of California has been awarded the maximum grant amount of USD 21 million  A variety of investors, having realized the benefits and future opportunities in this field, have invested more than USD 570 million across more than 30 instances, since 2017  The rising interest of stakeholders in exosome therapeutics is also reflected by the increasing number of partnerships established by various industry and non-industry players  Stakeholders have participated in various global events to discuss the research outcomes, and affiliated challenges as well as opportunities existing in this domain  At present, more than 30 start-ups are driving innovation in this domain; a variety of R&D initiatives have been undertaken by these players over the last few years for the development of exosome therapeutics  Lack of efficacy, COVID-19 pandemic, limited patient enrollment, and scarce funding are among the key reasons that have led to the discontinuation of studies sponsored by various industry and non-industry players  With the rising demand for therapeutic advances in drug safety, the market of exosome therapeutics is expected to grow at an annualized rate of 41% between 2029-2040  The projected market opportunity is likely to be well distributed across different routes of administration, types of formulations and key geographical regions Table of Contents 1. PREFACE 1.1. Scope of the Report 1.2. Market Segmentation 1.3. Research Methodology 1.4. Key Questions Answered 1.5. Chapter Outlines 2. EXECUTIVE SUMMARY 3. INTRODUCTION 3.1. Overview of Exosomes 3.1.1. Types of Extracellular Vesicles 3.1.1. Potential Sources of Exosomes 3.2. Exosome Biogenesis 3.2.1. Exosome Formation and Development Process 3.2.2. Secretion of Exosomes 3.3. Applications of Exosomes 3.4. Mechanism of Exosome Therapy 3.4.1. Exosome Drug Therapy 3.4.2. Exosome RNAi Therapy 3.4.3. Exosome Immunotherapy 3.5. Advantages of Exosome Therapies 3.6. Risks and Future Perspectives Associated with Exosome Therapeutics 4. EXOSOME THERAPEUTICS: MARKET LANDSCAPE 4.1. Analysis Methodology and Key Parameters 4.2. Exosome Therapeutics Market Landscape 4.2.1. Analysis by Phase of Development 4.2.2. Analysis by Technology Platform 4.2.3. Analysis by Type of Payload 4.2.4. Analysis by Derived Source 4.2.5. Analysis by Target Disease Indication(s) 4.2.6. Analysis by Therapeutic Area 4.2.7. Analysis by Phase of Development and Therapeutic Area 4.2.8. Analysis by Therapeutic Area and Route of Administration 4.2.9. Analysis by Route of Administration 4.2.10 Analysis by Area of Application 4.2.11. Analysis by Type of Therapy 4.2.12. Analysis by Dosing Frequency 4.2.13. Analysis by Type of Therapy (By Method of Composition) 4.2.14. Analysis by Line of Treatment 4.3. Exosome Therapeutics Developers 4.3.1. Analysis by Year of Establishment 4.3.2. Analysis by Company Size 4.3.3. Analysis by Location of Headquarters 4.3.4. Most Active Players: Analysis by Number of Therapeutics 5. EXOSOME THERAPEUTICS DEVELOPERS: COMPANY PROFILES 5.1. Coya Therapeutics 5.1.1. Company Overview 5.1.2. Product Portfolio 5.1.3. Recent Developments and Future Outlook 5.2. Codiak BioSciences 5.3.1. Company Overview 5.3.2. Product Portfolio 5.3.3. Clinical Trial Information 5.3.4. Recent Developments and Future Outlook 5.4. Evox Therapeutics 5.4.1. Company Overview 5.4.2. Product Portfolio 5.4.3. Recent Developments and Future Outlook 5.5. Curexsys 5.5.1. Company Overview 5.5.2. Product Portfolio 5.5.3. Recent Developments and Future Outlook 5.6. EV Therapeutics 5.6.1. Company Overview 5.6.2. Product Portfolio 5.6.3. Recent Developments and Future Outlook 5.7. SHIFTBIO 5.7.1. Company Overview 5.7.2. Product Portfolio 5.7.3. Recent Developments and Future Outlook 6. EXOSOME THERAPEUTICS: DRUG PROFILES 6.1. AEGLE Therapeutics 6.1.1. Company Overview 6.1.2. AGLE-102: Product Portfolio 6.1.2.1. AGLE-102: Clinical Trial Information 6.1.3. Recent Developments and Future Outlook 6.2. AVEM Healthcare 6.2.1. Company Overview 6.2.2. Ardoxso: Product Portfolio 6.2.2.1. Ardoxso: Clinical Trial Information 6.2.3. Recent Developments and Future Outlook 6.3. Cellular Biomedicine Group 6.3.1. Company Overview 6.3.2. Financial Information 6.3.3. haMPC-Exos: Product Portfolio 6.3.3.1. haMPC-Exos: Clinical Trial Information 6.3.4. hMSC-Exos: Product Portfolio 6.3.4.1. hMSC-Exos: Clinical Trial Information 6.3.5. Undisclosed Drug 1: Product Portfolio 6.3.5.1. Undisclosed Drug 1: Clinical Trial Information 6.3.6. Recent Developments and Future Outlook 6.4. OBCTCD24 6.4.1. Company Overview 6.4.2. CovenD24: Product Portfolio 6.4.2.1. CovenD24: Clinical Trial Information 6.4.3. Recent Developments and Future Outlook 6.5. ReNeuron 6.5.1. Company Overview 6.5.2. Financial Information 6.5.3. Undisclosed Drug 1: Product Portfolio 6.5.3.1. Undisclosed Drug 1: Clinical Trial Information 6.5.4. Recent Developments and Future Outlook 6.6. Stem Cell Medicine 6.6.1. Company Overview 6.6.2. Undisclosed Drug 1: Product Portfolio 6.6.3. Recent Developments and Future Outlook 7. CLINICAL TRIAL ANALYSIS 7.1. Analysis Methodology and Key Parameters 7.2. Exosome Therapeutics: List of Clinical Trials 7.2.1. Analysis by Trial Status 7.2.2. Analysis by Trial Registration Year 7.2.3. Analysis by Sponsor / Collaborator 7.2.4. Analysis by Trial Registration Year and Type of Study 7.2.5. Analysis by Trial Registration Year and Trial Status 7.2.6. Analysis by Annual Number of Patients Enrolled 7.2.7. Analysis by Study Design 7.2.8. Analysis by Age Category 7.2.9. Analysis by Phase of Development and Trial Status 7.2.10. Analysis by Phase of Development and Patients Enrolled 7.2.11. Most Active Industry Players: Analysis by Number of Registered Trials 7.2.12. Most Active Non-Industry Players: Analysis by Number of Registered Trials 7.2.13. Analysis by Trial Location 7.2.14. Analysis by Trial Status and Geography 7.2.15. Analysis by Trial Status, Patients Enrolled and Geography 8. ACADEMIC GRANT ANALYSIS 8.1. Analysis Methodology and Key Parameters 8.2. Exosome Therapeutics: List of Academic Grants 8.3. Analysis by Year of Grants Awarded 8.4. Analysis by Amount Awarded per Year 8.5. Analysis by Type of Funding Institute Center 8.6. Analysis by Support Period 8.7. Analysis by Purpose of Grant 8.8. Word Cloud Analysis: Emerging Focus Area 8.9. Analysis by Grant Activity Code 8.10. Analysis by Location of Recipient Organizations 8.11. Popular Recipient Organizations: Analysis by Number of Grants 8.12. Popular Recipient Organizations: Analysis by Amount Awarded 8.13. Analysis by Type of Recipient Organization 8.14. Analysis by Study Section 8.15. Analysis by Type of Grant Application 8.16. Analysis by Funding Institute Center and Support Year 9. GLOBAL EVENT ANALYSIS 9.1. Chapter Overview 9.2. Scope and Methodology 9.3. List of Global Events Related to Exosomes 9.3.1. Analysis by Year of Event 9.3.2. Analysis by Event Platform 9.3.3. Analysis by Type of Event 9.3.4. Analysis by Region 9.3.5. Most Active Organizers: Analysis by Number of Events 9.3.6. Most Active Speakers: Analysis by Number of Events 9.3.7. Most Active Industry Participants: Analysis by Number of Events 9.3.8. Most Active Non-Industry Participants: Analysis by Number of Events 9.3.9. Analysis by Designation of Participant 9.3.10. Analysis by Affiliated Department of Participant 9.3.11. Word Cloud Analysis: Evolutionary Trends in Event Agenda / Key Focus Area 10. PARTNERSHIPS AND COLLABORATIONS 10.1. Chapter Overview 10.2. Partnership Models 10.3. Exosome Therapeutics: List of Partnerships and Collaborations 10.3.1. Analysis by Year of Partnership 10.3.2. Analysis by Type of Partnership 10.3.3. Analysis by Year and Type of Partnership 10.3.4. Analysis by Company and Type of Partnership 10.3.5. Analysis by Type of Technology Platform 10.3.6. Analysis by Type of Partner 10.3.7. Most Active Players: Analysis by Number of Partnerships 10.3.8. Word Cloud Analysis: Emerging Focus Areas 10.3.9. Analysis by Target Disease Indication(s) 10.3.10.Analysis by Therapeutic Area 10.3.11.Analysis by Therapeutic Area and Type of Partnership 10.3.12. Regional Distribution of Partnerships 10.3.13. Distribution by Geography 11. FUNDING AND INVESTMENT ANALYSIS 11.1. Analysis Methodology and Key Parameters 11.2. Type of Funding 11.3. Exosome Therapeutics: List of Funding Instances 11.4. Analysis by Year of Funding 11.5. Analysis by Amount Invested 11.6. Analysis by Type of Funding 11.7. Analysis by Type of Funding and Amount Invested 11.8. Analysis by Purpose of Funding 11.9. Analysis by Target Disease Indication(s) 11.10. Analysis by Therapeutic Area 11.11. Most Active Players: Analysis by Number of Funding Instances 11.12. Most Active Players: Analysis by Amount Raised 11.13. Active Investors: Analysis by Number of Funding Instances 11.14. Distribution by Geography 11.15. Summary of Funding Activity 12. START-UP HEALTH INDEXING 12.1. Analysis Methodology and Key Parameters 12.2. Analysis by Pipeline Strength 12.3. Analysis by Pipeline Maturity 12.4. Analysis by Indication Diversity 12.5. Analysis by Number of Partnerships 12.6. Analysis by Financial Support 12.7. Start-up Health Indexing: Roots Analysis Perspective 12.8. Most Active Start-ups 13. CASE STUDY: EXOSOME DEVELOPMENT AND MANUFACTURING SERVICE PROVIDERS 13.1. Chapter Overview 13.2. Exosome Development and Manufacturing Service Providers Landscape 13.2.1. Analysis by Year of Establishment 13.2.2. Analysis by Company Size 13.2.3. Analysis by Location of Headquarters 13.2.4. Analysis by Location of Headquarters and Company Size 13.3. Analysis by Type of Service(s) Offered 13.3.1. Analysis by Method of Isolation 13.3.2. Analysis by Method of Purification 13.3.3. Analysis by Method of Characterization 13.3.4. Analysis by Method of Exosome Manufacturing 13.3.5. Analysis by Scale of Operation 13.3.6. Analysis by Scalability 14. DRUG FAILURE ANALYSIS 14.1. Methodology and Key Parameters 14.2. Exosome Therapeutics: List of Failed Drug Candidates 14.2.1. Analysis by Trial Start and Discontinuation Year 14.2.2. Analysis by Trial Status of Discontinuation 14.2.3. Analysis by Target Disease Indication(s) 14.2.4. Analysis by Route of Administration 14.2.5. Analysis by Type of Sponsor 14.2.6. Analysis by Reasons for Drug Failure 14.2.7. Word Cloud Analysis: Emerging Focus Area 15. MARKET SIZING AND OPPORTUNITY ANALYSIS 15.1. Forecast Methodology and Key Assumptions 15.2. Global Exosome Therapeutics Market, 2029-2040 15.2.1. Exosome Therapeutics Market for Allogeneic Therapy, 2029-2040 (USD Million) 15.2.2. Exosome Therapeutics Market for Autologous Therapy, 2029-2040 (USD Million) 15.2.3. Exosome Therapeutics Market for Degenerative Meniscal Injury, 2031-2040 (USD Million) 15.2.4. Exosome Therapeutics Market for Dystrophic Epidermolysis Bullosa, 2030-2040 (USD Million) 15.2.5. Exosome Therapeutics Market for Fistula Perianal, 2029-2040 (USD Million) 15.2.6. Exosome Therapeutics Market for Retinitis Pigmentosa, 2029-2040 (USD Million) 15.2.7. Exosome Therapeutics Market for Dermatological Disorders, 2030-2040 (USD Million) 15.2.8. Exosome Therapeutics Market for Muscoskeletal Disorders, 2031-2040 (USD Million) 15.2.9. Exosome Therapeutics Market for Ophthalmic Disorders, 2029-2040 (USD Million) 15.2.10. Exosome Therapeutics Market for Rectal Disorders, 2029-2040 (USD Million) 15.2.11. Fistula Tract Exosome Therapeutics Market, 2029-2040 (USD Million) 15.2.12. Intra-articular Exosome Therapeutics Market, 2031-2040 (USD Million) 15.2.13. Intra-ocular Exosome Therapeutics Market, 2029-2040 (USD Million) 15.2.14. Exosome Therapeutics Market Geographical Distribution, 2029-2040 (USD Million) 15.2.15. Erciyes University’s Drug: Sales Forecast, 2029-2040 (USD Million) 15.2.16. Synovial Fluid-Derived Mesenchymal Stem Cells: Sales Forecast, 2031-2040 (USD Million) 15.2.17. AGLE-102: Sales Forecast, 2030-2040 (USD Million) 15.2.18. Trehan University of Medical Sciences’ Drug: Sales Forecast, 2029-2040 (USD Million) 15.2.19. ReNeuron’ Drug: Sales Forecast, 2029-2040 (USD Million) 16. EXECUTIVE INSIGHTS 16.1. Capricor Therapeutics 16.1.1. Company Snapshot 16.1.2. Interview Transcript: Xavier Avat, Chief Business Officer 16.2. Exogenus Therapeutics 16.2.1. Company Snapshot 16.2.2. Interview Transcript: Patricia C. Freire, R&D and Innovation Manager 16.3. ILIAS Biologics 16.3.1. Company Snapshot 16.3.2. Interview Transcript: Soonho Song, Chief Business Officer 17. APPENDIX 1: TABULATED DATA 18. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS To view more details on this report, click on the link https://www.rootsanalysis.com/reports/exosome-therapeutics-market.html You may also be interested in the following titles: Lab Automation Market Cannabis Testing Market You may also like to learn what our experts are sharing in Roots educational series: Antiviral Drugs Development: Are we Prepared for the Next Viral Pandemic? Exploring How Artificial Intelligence Is Transforming Digital Pathology About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com #ExosomeTherapeuticsMarketTrends #ExosomeTherapeuticsMarketGrowth #exosometherapies #MSCderivedexosomes #Extracellularvesicles

The exosome therapeutics market is anticipated to grow at a commendable pace by 2040, claims Roots Analysis Owing to their potential in effective intracellular shuttling, therapeutic molecular delivery and treatment of multiple disorders, exosomes have garnered significant attention of researchers and industry stakeholders in the past few years Roots Analysis is pleased to announce the publication of its recent study, titled, “Exosome Therapeutics Market, 2022-2040.” The report features an extensive study on the current market landscape, offering an informed opinion on the likely evolution of the exosome therapies in the treatment of various diseases. To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/exosome-therapeutics-market/request-sample.html The study presents an in-depth analysis, highlighting the diverse capabilities of players engaged in this domain, across different geographies. In addition to other elements, the study includes:  A detailed assessment of the current market landscape of drug developers engaged in the development of exosome (membrane bound extracellular vesicles) therapeutics.  Detailed profiles of key players involved in the development of exosome therapeutics (shortlisted on the basis of the number of pipeline products).  Detailed drug profiles of key therapeutics in the highest phase of development.  A detailed analysis of more than 50 completed, ongoing and planned clinical studies of exosome therapeutics.  An in-depth analysis of more than 500 academic grants that have been awarded to research institutes engaged in exosome therapeutics-related projects.  A detailed analysis of the global events attended by the exosome therapy developers.  An analysis of the partnerships that have been established in this domain, in the recent past.  An in-depth analysis of various investments made since 2017.  An analysis of start-ups / small companies engaged in the development of exosome therapeutics.  A case study highlighting the companies engaged in offering exosome development and manufacturing services.  An in-depth analysis of exosome therapeutics that failed to progress to later stages of clinical development.  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)  Type of Therapeutic  Allogeneic Therapy  AutologousTherapy  Target Indication(s)  Degenerative Meniscal Injury  Dystrophic Epidermolysis Bullosa  Fistula Perianal  Retinitis Pigmentosa  Therapeutic Area  Dermatological Disorders  Muscoskeletal Disorders  Ophthalmic Diseases  Rectal Disorders  Route of Administration  Fistula Tract  Intra-articular  Intra-ocular  Geography  North America  Europe  Asia-Pacific and Rest of the World Key companies covered in the report  Codiak BioSciences  Coya Therapeutics  Curexsys  EV Therapeutics  Evox Therapeutics  SHIFTBIO  AEGLE Therapeutics  AVEM Healthcare  Cellular Biomedicine Group  OBCTCD24  ReNeuron  Stem Cell Medicine For more information, please click on the following link: https://www.rootsanalysis.com/reports/exosome-therapeutics-market.html You may also be interested in the following titles: 1. Quantum Computing in Drug Discovery Services Market : - Industry Trends and Global Forecasts, 2023-2035 2. Viral Clearance and Viral Testing Services Market : - Industry Trends and Global Forecasts, 2023-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com

PRESENTLY, AROUND 80 4D BIOPRINTERS AND SMART BIOMATERIALS ARE BEING DEVELOPED BY VARIOUS INDUSTRY AND NON-INDUSTRY PLAYERS, EQUIPPED WITH THE VITAL CAPABILITIES THAT CAN BE USED ACROSS A WIDE RANGE OF APPLICATION AREAS During our research, we were able to identify close to 80 bioprinters and smart biomaterials that are in different stages of development for the treatment of various diseases. It is worth highlighting that 50% players developing 4D bioprinters have established their presence in the domain after 2012. This indicates that the market is driven by the efforts of new players, majority of which have around 10 years of experience; prominent examples include (in reverse chronological order of their year of establishment) BRIGHTER (2020), Readily3D (2020), TissueLabs (2019) and Nuclera (2013). It is worth mentioning that pre-1985, seven companies have been established; examples include (in reverse chronological order of their year of establishment) 3D Systems (1983), University of Wollongong (1975) and Rutgers University (1766). Presently, the 4D bioprinting technology is being explored for use across various application areas in the biomedical industry, leading to an increase in opportunities within this domain To request a sample copy / brochure of this report, please visit https://www.rootsanalysis.com/reports/4d-bioprinting-market/request-sample.html Further, 55% players developing smart biomaterials have entered this field before 1970. This indicates that the market is driven by the efforts of well-established players, majority of which have more than 45 years of experience; prominent examples include (in reverse chronological order of their year of establishment) University of Birmingham (1900), RWTH Aachen University (1870), University of Georgis (1785) and Harvard University (1636). It is worth mentioning that post 2014, six new companies have been established; examples include (in reverse chronological order of their year of establishment) Instituto de Nanociencia y Materiales de Aragón (2020), 4D Biomaterials (2018), NanoBio Lab (2018), 1ST GRAPHENE (2016), NanoRegMed (2016) and Grolltex (2015) Moreover, companies developing 4D bioprinters and smart biomaterials have been segregated under three categories, namely small (less than 50 employees), mid-sized (51-500 employees) and large companies (more than 500 employees). It is important to mention that, for the purpose of this analysis, information has been sourced primarily from company websites and other reliable sources, such as LinkedIn. As can be observed in the figure, polymer (58%) emerged as the most preferred type of biomaterial. This is followed by natural type of biomaterial (49%). It is worth mentioning that biomaterials offer variety of applications such as making implants / protheses and medical devices, as they have the unique ability to replace or restore the lost or impaired bodily functions. Further, 58% 4D bioprinters have already been commercialized while 42% 4D bioprinters are under development phase. Examples of some commercialized 4D bioprinters include (in alphabetical order, no selection criteria) NGB-R, Organ.Aut, Origin One and Tomolite. Moreover, laser-based technology is the most preferred (42%) type of technology used in 4D bioprinters. This can be attributed to the fact that lased-based technology utilizes a nozzle free approach. The presence of nozzle can harm the cell viability sometimes, while its absence significantly improves the same. Further, this nozzle-free approach also allows to adjust the viscosity of bioink as per the need. As can be observed in the figure, 23% polymer-based smart biomaterials and 8% smart biomaterials made of natural components have already been commercialized. While 44% polymer-based smart biomaterials and 20% smart biomaterials made of natural components are under development. Notable examples of commercialized polymer-based smart biomaterials include (in alphabetical order, no selection criteria) 4Degra resin ink, SLA Resins and Porcine collagen-based hydrogel. Further, maximum number of smart biomaterials (23%) are available in sheet form. This is followed by 14% smart biomaterials available in liquid form. Further, there are 11% smart biomaterials available in gel and versatile forms, each. Moreover, most of the smart biomaterials (28) marketed / being developed can be used in the field of tissue engineering and regenerative medicine. It is worth mentioning that 4D printed pictures of tissues are used to manufacture patient-specific tissue structures using computer-aided design (CAD), along with other digital imaging methods such as magnetic resonance imaging (MRI) and X-ray computed tomography (CT). This is followed by six smart biomaterials that can be applied in the domain of orthopedics. For additional details, please visit https://www.rootsanalysis.com/reports/4d-bioprinting-market.html or email sales@rootsanalysis.com You may also be interested in the following titles: 1. Quantum Computing in Drug Discovery Services Market : - Industry Trends and Global Forecasts, 2023-2035 2. Viral Clearance and Viral Testing Services Market : - Industry Trends and Global Forecasts, 2023-2035 About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. Contact: Ben Johnson +1 (415) 800 3415 Ben.johnson@rootsanalysis.com